Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tonix Pharmaceuticals Holding (TNXP) Long-Term Debt Repayments (2024 - 2025)

Tonix Pharmaceuticals Holding (TNXP) has 2 years of Long-Term Debt Repayments data on record, last reported at $50000.0 in Q2 2025.

  • For Q2 2025, Long-Term Debt Repayments fell 92.91% year-over-year to $50000.0; the TTM value through Sep 2025 reached $10.4 million, changed N/A, while the annual FY2024 figure was $2.4 million, N/A changed from the prior year.
  • Long-Term Debt Repayments reached $50000.0 in Q2 2025 per TNXP's latest filing, down from $9.6 million in the prior quarter.
  • Across five years, Long-Term Debt Repayments topped out at $9.6 million in Q1 2025 and bottomed at $50000.0 in Q2 2025.